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Edited by Laszlo NagyAbstract Peripheral administration of baclofen signiﬁcantly
reduced food intake and body weight increase in both diabetic
(db/db) and diet-induced obese mice for 5 weeks, whereas it
had no signiﬁcant eﬀects on energy balance in their lean control
mice. Despite the decreased body weight, neuropeptide Y expres-
sion in the arcuate nucleus was signiﬁcantly decreased, whereas
pro-opiomelanocortin expression was signiﬁcantly increased by
baclofen treatment. These data demonstrate that the inhibitory
eﬀects of baclofen on body weight in the obese mice were medi-
ated via the arcuate nucleus at least partially, and suggest that
GABAB agonists could be a new therapeutic reagent for obesity.
 2007 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Neuropeptide Y; Pro-opiomelanocortin1. Introduction
Among peripheral signals related to energy balance, leptin,
an adipocyte-derived hormone, plays a critical role in energy
balance as evidenced by obesity resulting from a genetic deﬁ-
ciency of leptin (ob/ob mice) or its receptor (db/db mice) [1].
Although leptin decreases body weight by inhibiting neuropep-
tide Y (NPY) [2] and stimulating pro-opiomelanocortin
(POMC) [3] expression in the arcuate nucleus, plasma leptin
levels are elevated in obesity probably due to reduced eﬃcacy
of brain leptin transport [4] or desensitization of its receptors
[5]. Thus, while the amelioration of leptin signaling at the level
of the arcuate nucleus could be an ideal treatment for obesity
given that the nucleus is the ‘‘ﬁrst order neurons’’ in the regu-
lation of energy balance [6], reagents other than leptin are
required to improve leptin resistance.Abbreviations: NPY, neuropeptide Y; POMC, pro-opiomelanocortin;
DIO, diet-induced obesity; 3-APPA, 3-aminopropylphosphonic acid;
WAT, white adipose tissue
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0014-5793/$32.00  2007 Federation of European Biochemical Societies. Pu
doi:10.1016/j.febslet.2007.09.011In a previous study, we demonstrated that insulin, another
peripheral hormone which inhibits food intake by acting on
the hypothalamus, inhibited the NPY gene expression in the
arcuate nucleus indirectly through GABAB systems [7]. As
there is cross-talk between leptin and insulin signaling in the
hypothalamus [6], these data suggest that GABAB signaling
might act downstream of leptin receptors as well in the hypo-
thalamus.
In this study, we examined whether a GABAB agonist, bac-
lofen, dissolved in drinking water, which crosses the blood–
brain barrier [8], could improve obesity in db/db mice as well
as in diet-induced obesity (DIO) mice.2. Materials and methods
2.1. Animals
Male 5-week-old db/db or heterozygous db/+m mice on a C57BL/
KsJ background were obtained from Chubu Science Materials (Na-
goya, Japan). Male 5-week-old C57BL/6N mice were obtained from
CLEA Japan Inc. (Tokyo, Japan). Mice were housed individually in
plastic cages under controlled conditions (23.0 ± 0.5 C; lights on
9:00–21:00). Mice in the treatment group were orally administered
one of the following GABAB agonists dissolved in drinking water in
whole treatment periods: (±)-b-(aminomethyl)-4-chloro-benzene-
propanoic acid ((±)-baclofen), (racemic baclofen; 4 · 106 M–100 ·
106 M, Sigma), R(+)- or S()-baclofen hydrochloride (40 · 106 M,
Sigma), 3-aminopropyl(methyl)phosphinic acid (SKF 97541; 10 ·
106 M, BIOMOL, Plymouth Meeting, PA), or 3-aminopropylphos-
phonic acid (3-APPA; 100 · 106 M, Sigma). In C57BL/6N mice,
administration of each drug in the treatment group was simultaneously
started with administration of high fat diet (60% of the calories as fat,
High fat diet 32: CLEA Japan Inc.). Five weeks after starting admin-
istration, mice which had been fasted for 6 h were decapitated after
collection of blood samples. All animal procedures were performed
in accordance with institutional guidelines for animal care at Nagoya
University Graduate School of Medicine.2.2. Measurement of blood glucose, HbA1c, insulin, leptin and
adiponectin
Blood glucose levels were measured by a glucose analyzer Antsense
(Horiba, Ltd., Kyoto, Japan), and the HbA1c levels were measured
using the glycohemoglobin analyzer HLC-723 GHbV (Tosoh Corpo-
ration, Yamaguchi, Japan). Plasma levels of insulin, leptin and adipo-
nectin were measured with enzyme-linked immunosorbent assay
commercial kits (insulin: Shibayagi, Gumma, Japan; leptin: Morinaga,
Yokohama, Japan; adiponectin: Otsuka, Tokyo, Japan).blished by Elsevier B.V. All rights reserved.
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The RNA probes were generated from the plasmids of NPY (kindly
provided by Dr. S.L. Sabol, Laboratory of Biochemical Genetics,
National Heart, Lung, and Blood Institute, National Institutes of
Health, Bethesda, MD) and POMC (kindly provided by Dr. Imaki,
Department of Bioregulation, Nippon Medical School Graduate
School, Kawasaki, Japan). In situ hybridization was performed as
described previously [7].Time after treatment (week) 
0
100
300
500
0 1 2 3 4 5
db/+m
C
Cu
m
ul
at
iv
e
fo
od
 in
ta
ke
 (k
ca
l)
Bac
Vehicle
700
600
400
200
Time after treatment (week) 
0
100
300
500
0 1 2 3 4 5
db/db
A
Cu
m
ul
at
iv
e
fo
od
 in
ta
ke
 (k
ca
l)
Bac
Vehicle
700
600
400
200
*
0 1 2 3 4 5
db/db
E
Vehicle
3-APPA
SKF97541
0
100
300
500
700
600
400
200C
um
ul
at
iv
e
fo
od
 in
ta
ke
 (k
ca
l)
Time after treatment (week) 
db/+m
0 1 2 3 4 5
G
0
100
300
500
700
600
400
200
Time after treatment (week) 
Cu
m
ul
at
iv
e
fo
od
 in
ta
ke
 (k
ca
l)
*
*
*
*
#
#*
#*
#*
#*
Vehicle
3-APPA
SKF97541
Fig. 1. Eﬀects of GABAB agonists on food intake and body weight in db/db a
baclofen group. *P < 0.05, Bac or SKF 97541 versus vehicle group. #P < 0.02.4. Histological analysis and morphometry
Histological analysis of epididymal white adipose tissue (WAT) was
performed as described previously [9].
2.5. Indirect calorimetry
The volume of O2 consumed VO2 was measured with an O2/CO2
metabolism measuring system (model MK-5000RQ, Muromachikikai,
Tokyo, Japan).Time after treatment (week) 
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Motor activity was measured for 24 h using an activity monitoring
system (model Supermex, Muromachikikai, Tokyo, Japan).
2.7. Statistical analyses
All results are expressed as mean values ± S.E. Multiple compari-
sons were evaluated by a one-way ANOVA followed by a Fisher’s pro-
tected least signiﬁcant diﬀerence test. Diﬀerences were considered
statistically signiﬁcant at P < 0.05.3. Results
3.1. Eﬀects of GABAB receptor agonists on food intake and body
weight in db/db mice
The food intake and body weight increase were signiﬁcantly
decreased by the administration of 100 · 106 M racemic baclo-
fen in db/db mice (Fig. 1A and B). On the other hand, the same
dose of baclofen did not aﬀect food intake or body weight sig-
niﬁcantly in heterozygous db/+m mice (Fig. 1C and D). SKF
97541 and 3-APPA also signiﬁcantly reduced food intake
and body weight increase in db/db mice (Fig. 1E and F), but
not in db/+m mice (Fig. 1G and H). In separate experiments,
db/db mice were given various doses of baclofen in drinking
water for 5 weeks. As shown in Fig. 2A and B, any concentra-
tion of baclofen in drinking water signiﬁcantly suppressed food
intake and body weight increase compared to the vehicle group
by the end of experiments. However, the diﬀerence in cumula-
tive food intake and body weight increase between vehicle and
100 · 106 M or 40 · 106 M baclofen groups reached statisti-
cal signiﬁcance 1 week after starting the administration,
whereas it took 2 or 4 weeks between vehicle and 10 ·
106 M or 4 · 106 M baclofen groups, respectively, following
the initiation of administration. Furthermore, 40 · 106 MVeh 10 40 100
Baclofen (x10-6M)
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Fig. 2. Eﬀects of various doses and each enantiomer of baclofen on food
means ± S.E. (n = 10). R-bac: R(+)-enantiomer of baclofen. S-bac: S()-enan
versus S-bac group.R(+)-enantiomer of baclofen was more eﬀective than the same
dose of S()-enantiomer of baclofen in decreasing food intake
and body weight increase in db/db mice (Fig. 2C and D). In the
following experiments, ‘‘baclofen’’ indicates 100 · 106 M
racemic baclofen.3.2. Eﬀects of GABAB receptor agonists on food intake and body
weight in DIO mice
Body weight was signiﬁcantly increased in mice fed the high
fat diet for 5 weeks (DIO mice: 34.3 ± 2.8 g) compared to those
fed regular chow for the same period (lean control mice:
23.6 ± 0.7 g). Baclofen treatment signiﬁcantly decreased food
intake and body weight increase in DIO mice but not in lean
control mice (Fig. 3A–D). SKF 97541 and 3-APPA also signif-
icantly reduced food intake and body weight increase in DIO
mice, but not in lean control mice (Fig. 3E–H).3.3. Eﬀects of baclofen on energy expenditure and motor activity
Baclofen signiﬁcantly increased O2 consumption in db/db
and DIO mice (Fig. 4A and E) but not in their lean control
mice (Fig. 4C and G). Baclofen treatment did not aﬀect motor
activity signiﬁcantly in either type of mice (Fig. 4B, D, F, H).
3.4. Eﬀects of baclofen on glucose intolerance and plasma
adipocytokine levels
The levels of blood glucose and HbA1c were signiﬁcantly
lower in baclofen groups compared to vehicle group in db/db
mice (Fig. 5A and B), and those of blood glucose and HbA1c
as well as plasma insulin were signiﬁcantly lower in baclofen
groups compared to vehicle group in DIO mice (Fig. 5K–
M). The levels of plasma leptin were signiﬁcantly increased
in baclofen groups compared to vehicle group in db/db miceIn
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Fig. 3. Eﬀects of GABAB agonists on food intake and body weight in DIO and lean control mice. The results are expressed as means ± S.E. (n = 10).
Bac: baclofen group. *P < 0.05, Bac or SKF 97541 versus vehicle group. #P < 0.05, 3-APPA versus vehicle group.
4860 I. Sato et al. / FEBS Letters 581 (2007) 4857–4864(Fig. 5D), whereas they were signiﬁcantly decreased in baclo-
fen groups compared to vehicle group in DIO mice
(Fig. 5N). The levels of plasma adiponectin were signiﬁcantly
increased in baclofen groups compared to vehicle group in
both db/db and DIO mice (Fig. 5E and O). Baclofen treatment
did not signiﬁcantly aﬀect any parameter in the lean control
mice (Fig. 5F–J, P–T).3.5. Eﬀects of baclofen on white adipose tissue
The weight of epididymal WAT was signiﬁcantly decreased
in baclofen groups compared to vehicle group, whereas there
were no signiﬁcant diﬀerences in the weight of subcutaneous
WAT between groups in db/db mice (Fig. 6A and B). On the
other hand, the weights of both epididymal and subcutaneous
WATs were signiﬁcantly decreased in baclofen groups com-
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I. Sato et al. / FEBS Letters 581 (2007) 4857–4864 4861pared to vehicle group in DIO mice (Fig. 6D and E). Morpho-
logical analyses revealed that the size of adipocytes in the
epididymal WAT was signiﬁcantly decreased in baclofen
groups compared to vehicle group in both db/db (vehicle:
14722 ± 322 lm2; baclofen: 8928 ± 554 lm2; P < 0.05) and
DIO (vehicle: 9189 ± 257 lm2; baclofen: 5748 ± 298 lm2;
P < 0.05) mice. Representative photographs of epididymal
WAT are shown in Fig. 6C and F.
3.6. Eﬀects of baclofen on NPY and POMC mRNA expression
in the arcuate nucleus of the hypothalamus
The NPY mRNA expression in the arcuate nucleus was sig-
niﬁcantly decreased in baclofen groups compared to vehiclegroup, whereas POMC mRNA levels were signiﬁcantly in-
creased in baclofen groups compared to vehicle group in both
db/db and DIO mice (Fig. 7).4. Discussion
In the present study, we examined the eﬀects of peripheral
administration of baclofen on energy balance in obese animal
models, db/db and DIO mice. Our data demonstrated that in
both db/db and DIO mice, (1) baclofen treatment signiﬁcantly
reduced food intake and body weight increase; (2) baclofen in-
creased O2 consumption without aﬀecting motor activities; (3)
the weight of WAT was signiﬁcantly decreased and glucose tol-
erance was signiﬁcantly improved by baclofen treatment; and
(4) NPY expression in the arcuate nucleus was signiﬁcantly de-
creased whereas POMC expression was signiﬁcantly increased
after administration of baclofen. The last ﬁnding is of particu-
lar interest, since it has been demonstrated that NPY expres-
sion in the arcuate nucleus was increased while the POMC
expression was decreased when food intake was restricted
and body weight was decreased [10]. In a previous study, we
demonstrated that baclofen signiﬁcantly suppressed NPY gene
expression in the arcuate nucleus in the hypothalamic organo-
typic cultures [7]. Taken together, it is likely that the baclofen
administered peripherally decreased body weight in the obese
mice by acting on the arcuate nucleus, at least partially.
Previous papers reported that administration of baclofen
increased [11], had no eﬀects on [12] or decreased [13,14] food
intake or body weight in rodents [11,14], chickens [12] and
non-human primates [13]. In addition to the diﬀerences in spe-
cies employed, routes (central or peripheral) or duration of
injection (acute or chronic) might explain the disparity be-
tween studies. To our knowledge, this is the ﬁrst study in which
the eﬀects of baclofen on energy balance were examined in ob-
ese subjects, and our results suggest that the eﬀects of baclofen
on food intake and body weight were clearly dependent on
whether the subjects were obese or not. Recent studies also
reported that baclofen reduced binge-eating in rats [15] and
humans [16]. Thus, it is likely that the activation of GABAB
signaling not only could improve obesity but also ameliorate
eating disorder.
R-enantiomer of baclofen has been shown to bind to GA-
BAB receptor sites with a higher degree of stereoselectivity
compared to the S-enantiomer [17]. Consistent with this,
R(+)-enantiomer of baclofen was more eﬀective than S()-
enantiomer of baclofen in reducing food intake in db/db mice.
Furthermore, SKF 97541 and 3-APPA, other GABAB ago-
nists, also decreased food intake and body weight in db/db
and DIO mice. These data suggest that inhibitory eﬀects of
baclofen on energy balance shown in the present study were
due to the speciﬁc action on its receptor.
In this study, baclofen decreased the weight and size of adi-
pocytes in db/db and DIO mice. These changes in adipocytes
per se could contribute to the improvement in insulin sensitiv-
ity [18], but also possibly caused increases in secretion of
adiponectin from adipose tissues [19], leading to further
improvement in glucose tolerance [20]. On the other hand,
while the plasma leptin levels were decreased in DIO mice by
baclofen treatment, they were elevated in db/db mice. A previ-
ous study demonstrated that serum leptin levels are elevated in
mice lacking the neuronal tyrosine phosphatase PTP1B, which
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Fig. 5. Eﬀects of baclofen on glucose tolerance and plasma adipocytokine levels. The results are expressed as means ± S.E. (n = 10). Veh: vehicle
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4862 I. Sato et al. / FEBS Letters 581 (2007) 4857–4864negatively regulates hypothalamic signals of insulin and leptin
[21,22], although the mice were hypersensitive to leptin [23].
We have also demonstrated in a recent paper that central
injection of melanotan II, an agonist for melanocortin type 4
receptors which are supposed to be downstream of leptin
[24], increased serum leptin levels in DIO rats while the body
weight was decreased by the injection [9]. Thus, it is possible
that activating leptin signaling in the hypothalamus could
potentially increase leptin release from adipose tissues and that
circulating leptin levels would be determined by a balance be-
tween adipose sizes and the signals from the hypothalamus,
although further studies are warranted to support this hypoth-
esis.Several kinds of drugs have been explored and used clinically
for the treatment of obesity. Among them, ciliary neurotrophic
factor (CNTF), originally developed as a potential treatment
for amyotrophic lateral sclerosis, is suggested to reduce food in-
take through down-regulation of NPY expression in the hypo-
thalamus [25]. However, the eﬃcacy of CNTF for obesity
treatment was reportedly limited by the development of the
antibodies in the treated patients [26]. Our data demonstrate
that aGABAB agonist baclofen has the potential to work down-
stream of leptin receptor and thereby reduce food intake and in-
crease energy expenditure in obese subjects. Furthermore, the
action of GABAB agonists on food intake is unique in that they
decreased food intake and body weight only in obese but not in
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were shown (C, F). Scale bars indicate 100 lm. Veh: vehicle group. Bac: baclofen group. *P < 0.05, versus vehicle group.
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Fig. 7. Eﬀects of baclofen on NPY and POMC gene expression in the arcuate nucleus in db/db and DIO mice. The results are expressed as
means ± S.E. (n = 10). Representative autoradiographs showing NPY and POMC mRNA expression in the arcuate nucleus are demonstrated (C, F).
Veh: vehicle group. Bac: baclofen group. *P < 0.05, versus vehicle group.
I. Sato et al. / FEBS Letters 581 (2007) 4857–4864 4863lean control mice. Although the detailed mechanisms by which
GABAB agonists aﬀected energy balance only in obese mice
have yet to be determined, it is suggested that GABAB agonists
would decrease only excessive adipose stores in obese subjects
when they are used clinically for the treatment of obesity.
In conclusion, our data provide the ﬁrst evidence that baclo-
fen reduced body weight by decreasing food intake and
increasing energy expenditure in obese mice, suggesting that
GABAB agonists could be new therapeutic reagents for obes-
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